A Review of Driving Restrictions in Patients at Risk of Syncope and Cardiac Arrhythmias Associated with Sudden Incapacity: Differing Global Approaches to Regulation and Risk

Andrei D Margulescu and Mark H Anderson

Morriston Cardiac Centre, Department of Cardiology, Morriston Hospital NHS Trust, Swansea, UK

Abstract
The ability to drive is a highly valued freedom in the developed world. Sudden incapacitation while driving can result in injury or death for the driver and passengers or bystanders. Cardiovascular conditions are a primary cause for sudden incapacitation and regulations have long existed to restrict driving for patients with cardiac conditions at high risk of sudden incapacitation. Significant variation occurs between these rules in different countries and legislatures. Quantification of the potential risk of harm associated with various categories of drivers has attempted to make these regulations more objective. The assumptions on which these calculations are based are now old and less likely to reflect the reality of modern driving. Ultimately, a more individual assessment of risk with a combined assessment of the medical condition and the patient’s driving behaviour may be appropriate. The development of driverless technologies may also have an impact on decision making in this field.

Keywords
Driving, incapacitation, sudden death, medical regulation, ethics, ICD, road accidents, driving restrictions, arrhythmia, risk of harm

Disclosure: The authors have no conflicts of interest to declare.

Received: 9 January 2019 Accepted: 9 April 2019 Citation: Arrhythmia & Electrophysiology Review 2019;8(2):90–8. DOI: https://doi.org/10.15420/aer.2019.13.2

Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Motor vehicle travel and driving has become a major component of daily living in the developed world. Sudden incapacity occurring while driving can result in accidents that may be fatal both for the driver and for bystanders. The regulatory approach aims to balance the risk to bystanders against the highly valued individual freedom of motorised mobility. In this article we review some of the concepts that are pivotal to this balancing act, compare variations in national approaches to regulation and ask whether it is time for some of the accepted tenets to be revised.

Syncope and Incapacitation as a Result of Arrhythmia
Sudden incapacity can result from a syncopal event, a sudden cardiac death (SCD), or a neurological event such as seizure or stroke. Syncope is defined as a transient loss of consciousness event that results from general brain hypoperfusion.1 Syncope can be neurally mediated, caused by orthostatic hypotension or by cardiac conditions – mostly arrhythmic events (either brady- or tachyarrhythmias). SCD is an unexpected death from a cardiac cause, which occurs within one hour from the start of any cardiac-related symptoms. It is irreversible if prompt resuscitation is not applied. SCD is mostly arrhythmic in nature, with ventricular tachycardia (VT) and VF responsible for >75% of cases.2

Cardiac pacemakers are used to treat patients with – or those at risk of developing – significant bradyarrhythmias, while ICDs are used to treat patients who are at high risk of SCD as a result of VT/VF. While pacemakers can effectively prevent the occurrence of bradyarrhythmias, ICDs do not prevent VT/VF but treat those rhythms once they happen by either overdrive antitachycardia pacing (ATP) or internal cardioversion. Syncope may still occur in patients who develop VT/VF despite having an ICD because of the time delay between arrhythmia occurrence, effective treatment and restoration of normal brain perfusion.

The following discussion will focus on the driving restrictions in patients at risk of syncope and cardiac arrhythmias associated with sudden incapacity.

Risk Estimate of Motor Vehicle Accident Fatalities in Patients at Risk of Syncope and Cardiac Arrhythmias
Driving Licence Categories
Driving licences are generally divided into private (group 1), and commercial (group 2). The definition of private and commercial drivers varies somewhat between countries (Table 1) but, in general, a private driver is a licensed driver who does not earn a living from driving and a commercial driver is a driver who earns a living from driving and/or is licensed to drive large passenger or goods-carrying vehicles. Categories for taxi drivers vary between group 1 and group 2 standards and may be locally determined.
Syncope and Cardiac Arrhythmias

Accident and fatality rates also vary according to age. The rate of death in car accidents is highest in individuals aged 20–29 years and in 2016 there was almost a fourfold difference in road accident fatalities between the ‘safest’ and the ‘least safe’ European countries: Norway (26 fatalities per million population) and Romania (97 fatalities per million population).1 However, while some of the difference may relate to mileage driven, cultural approaches to risk are also an important factor.

Table 1: Definition of Driving Licence Groups

| Group | EU | UK | US | Australia | Japan |
|-------|----|----|----|-----------|-------|
| Group 1 | Ordinary motorcycles, cars, small vehicles with or without a trailer (categories A, B) | Similar to EU. Maximal vehicle weight <3,500 kg | Any not fulfilling commercial driver criteria | Drivers of cars and light rigid vehicles. Cars are defined as vehicles of <4.5 tonnes, and seating up to 12 adults (including the driver). | - Driver of motorcycles, automobiles, other vehicles with or without a trailer, AND - Does not earn a living from driving |
|       |     |    |    |           |       |
| Group 2 | Drivers of vehicles weighing >3.5 tonnes. Drivers of passenger-carrying vehicles with more than 8 seats including the driver (categories C, D and E [vehicles with a trailer]) | Similar to EU. | Any driver of: vehicles weighing >26,001 pounds; truck with double/triple trailers; truck carrying hazardous materials; passenger vehicles designed to carry >16 passengers including the driver | Any not fulfilling private driver criteria | Any two-axle or three-axle rigid vehicle of >8 tonnes (or 9 tonnes with a trailer) | Driver who earns a living from driving, including taxi, bus, ambulance |

General Statistics on Road Traffic Accidents

Driving a car is a central part of life in developed societies. For example, more than 85% of Americans own a car and almost 270 million vehicles are registered in the US alone (of which more than 190 million are "light duty, short wheelbase" vehicles).3 However, motor vehicle accidents are a leading cause of death worldwide. Road injuries – including accidents involving all forms of road transportation systems, and pedestrians – killed more than 1.4 million people in 2016.6 In UK, 1,793 people were killed in road accidents in 2017, 44% of which were drivers.5

The risk of death related to driving is highly variable between countries. Road traffic death rates in low- and middle-income countries are more than double those in high-income countries.4 However, wide disparities exist even among developed countries. For example, per capita road fatalities in the US are more than double those in Denmark, and in 2016 there was almost a fourfold difference in road accident fatalities between the ‘safest’ and the ‘least safe’ European countries: Norway (26 fatalities per million population) and Romania (97 fatalities per million population).7,8 While some of the difference may relate to mileage driven, cultural approaches to risk are also an important factor.

Acceptable Risk of Road Traffic Accidents

Driving carries risk but is a major part of life in many societies, so it follows that these societies accept an intrinsic risk of harm (RH) to self and others because of driving. Nationally defined regulations have implicitly balanced risk and benefit for decades. An attempt to formalise this balancing act emerged from a Canadian Cardiovascular Society conference in 1992 (updated in 2003).9 In this document, the annual RH as a result of driving was defined as:

\[ RH = TD \times V \times SCI \times Ac \]

where:
- TD is the time spent driving;
- V is the type of vehicle;
- SCI is the risk of sudden incapacitation; and
- Ac is the probability that an episode of sudden incapacitation will result in a fatal or injury-producing accident.

- TD is 0.25 (25%) for professional drivers because the average time spent driving is 6 hours per day; and 0.04 (4%) for social drivers because they spend, on average, 1 hour driving per day.
- V is 1 for trucks and 0.28 for family cars because, on average, accidents involving trucks cause 7.2% of fatalities, despite causing only 2.0% of road accidents (2.0 ÷ 7.2% = 0.28).
- SCI is 0.01 (1%), which was the estimated annual risk of SCD of a truck driver who had not had an acute MI within the previous 3 months, is in functional class I (asymptomatic), has a negative exercise tolerance test, is able to perform at least seven metabolic equivalents of task during the treadmill test, and has no documented ventricular arrhythmias. This driver was historically allowed to drive by Canadian laws, so this was set as the acceptable risk threshold in the RH formula. The 1% mortality per year also holds true for men in the Western population aged >65 years and this limit has been used for maximal annual risk allowance for commercial pilots in aviation risk assessment (the 1% rule).10

Source: Watanabe E et al.; DVLA 2018; EUR-Lex Directive 2006/126/EC; The Expert Group on Driving and Cardiovascular Disease; Lococo et al; Canadian Council of Motor Transport Administrations; Australian.
Overall, patients with a history of syncope have a higher risk of motor vehicle accidents compared with asymptomatic subjects. A Danish nationwide survey identified more than 41,000 patients with syncope and compared their motor vehicle accident rate to the general Danish population. During an average 2-year follow up, 4.4% of patients had a vehicle accident, 23.7% of which led to major injury and 0.3% to death. When an accident occurred there was no difference in the risk of serious injury between the syncope and general populations. The crude incidence rate of motor vehicle accident was 1.83-times higher in patients with syncope compared with the general population (20.6 per 1,000 person-years versus 12.1 per 1,000 person-years). The 5-year accident risk in patients aged 18 to 69 years with syncope was 8.2%, compared with 5.1% in the general population.

The risk of syncope recurrences is highest in the first year after the initial event, then it gradually tapers off and reaches a plateau after 5 years. About one-quarter of syncopal episodes while driving remain undiagnosed. The annual recurrence rate of undiagnosed syncope (15–21%) lies in between the recurrence rate of neurally mediated syncope and syncope of other aetiologies, but the actual risk of recurrence while driving is low at <1.1% per year, which is similar to the risk of SCI in the RH formula. It follows that the highest risk of recurrence while driving actually resides with neurally-mediated syncope, but the actual RH of this type of syncope rarely reaches the threshold of unacceptable societal risk (0.005% per year). Bradycardyrrhythmic syncope recurrences are usually mitigated by implantation of a permanent pacemaker. AVNRT and AVRT are effectively treated and even cured with radiofrequency ablation. The case of VT/VF will be discussed below, under the headings for ICDs.

See Table 2 for full details of syncope guidance depending on country or guideline document. We endorse the recommendations valid in the UK on driving restrictions for patients with syncope, supraventricular tachycardia, following ablation procedures and with pacemaker devices. Our personal opinion regarding private drivers with ICDs will be discussed briefly below.

ICDs
In 2011, around 400,000 ICDs were implanted each year worldwide, two-thirds of which were new implants. ICDs are implanted for primary or secondary prevention of SCD. Primary prevention refers to patients who have never had but are at risk of having a VT/VF event. Secondary prevention refers to patients who have had a VT/VF event. There are a variety of conditions that may predispose a patient to SCD and each carries a particular risk. In the adult population, the majority of SCD events – approximately 80% – appear in patients with coronary artery disease. ICDs are effective in treating sudden ventricular tachyarrhythmic events that can cause SCD. However, ICDs do not prevent such events. With VF, loss of consciousness is usual as the ICD typically takes 10–15 seconds to deliver therapy (longer for subcutaneous ICDs). As such, establishing the risk of syncopal events caused by VT/VF in patients with ICDs is important to assess the RH.

The average annual risk of shock while driving in patients with ICDs is approximately 1.5%. Studies have documented that the risk of syncope associated with appropriate ICD shocks in patients who have had an ICD implanted for secondary prevention ranges from 2.0% to 16.0% (average 11.2%). For primary prevention, the risk of syncope would be much lower. However, the exact risk of syncope in patients with ICDs is influenced by various factors, including the type of ICD, the specific condition treated, and the individual patient's response to the therapy.

Risk Assessment for Patients at Risk of Syncope and Cardiac Arrhythmias Associated with Sudden Incapacity
Syncope
Data from the Framingham Heart Study suggest that the incidence of syncope in the general population is between 3% and 6% at 10 years. Among patients with syncope, 3–10% of syncopal events appear while driving; 85% of these patients have recurrent syncope but in a few the first syncope occurs while driving. The causes of syncope while driving are the same as for the general population; 35–38% are neurally mediated, 5–7% are caused equally by orthostatic hypotension, bradyarrhythmias and VTs, and 2–4% are caused by supraventricular tachycardias (almost all of them either atrioventricular nodal re-entrant tachycardia [AVNRT] or atrioventricular re-entrant tachycardia [AVRT]). During long-term follow up (8 years), the recurrence rate of syncope was similar in patients who had experienced the first syncopal event while driving and those who had not; 34–39% for neurally-mediated syncope, 7–13% for bradyarrhythmias, and 3–4% for VT and supraventricular tachycardias. Malignant arrhythmias causing SCD (fast VT/VF) are rare. A retrospective study performed in Germany estimated that 0.4% of all road traffic accidents are caused by the driver having a SCD event while driving.
### Table 2: Recommendations of Driving Restrictions

| Cardiovascular condition                                                                 | Driving licence group | Europe | US | Canada | Australia | Japan |
|-----------------------------------------------------------------------------------------|-----------------------|--------|----|--------|-----------|-------|
| **Syncope**                                                                             |                       |        |    |        |           |       |
| **Group 1**                                                                             |                       |        |    |        |           |       |
| 1. Single syncope or recurrent syncopal episodes occurring in known low-risk circumstances | 1. No restrictions     |        |    |        |           |       |
| 2. All other cases of recurrent syncopal episodes                                         | 2. Driving for >6 months, pending additional investigations |        |    |        |           |       |
| **Group 2**                                                                             |                       |        |    |        |           |       |
| 1. Single syncope or recurrent syncopal episodes occurring in known low-risk circumstances | 1. No restrictions     |        |    |        |           |       |
| 2. All other cases of recurrent syncope episodes                                          | 2. Driving for >6 months, pending additional investigations |        |    |        |           |       |
| 2.1 Typical vasovagal                                                                  |                       |        |    |        |           |       |
| a) while standing                                                                      | 1. No restrictions     |        |    |        |           |       |
| b) while sitting                                                                       | 2. Driving for >3 months, requires investigations         |        |    |        |           |       |
| 2.2 Vasovagal without prodrome / unexplained                                            |                       |        |    |        |           |       |
|                                                                                       | 1. No driving for 12 months                                 |        |    |        |           |       |
| **Group 3**                                                                             |                       |        |    |        |           |       |
| 1. Single syncope or recurrent syncopal episodes occurring in known low-risk circumstances | 1. No restrictions     |        |    |        |           |       |
| 2. All other cases of recurrent syncope episodes                                          | 2. Driving for >6 months, pending additional investigations |        |    |        |           |       |
| 2.1 Typical vasovagal                                                                  |                       |        |    |        |           |       |
| a) while standing                                                                      | 1. No restrictions     |        |    |        |           |       |
| b) while sitting                                                                       | 2. Driving for >3 months, requires investigations         |        |    |        |           |       |
| 2.2 Vasovagal without prodrome / unexplained                                            |                       |        |    |        |           |       |
|                                                                                       | 1. No driving for 12 months                                 |        |    |        |           |       |
### Table 2: Continued

| Cardiovascular condition | Driving licence group | Europe (professional guideline) | EC recommendations 2013 (proposal to update Directive 2006/126/EC) | UK | Germany | US | Canada | Australia | Japan |
|--------------------------|-----------------------|---------------------------------|---------------------------------------------------------------|----|---------|----|--------|----------|-------|
| Supraventricular arrhythmias | Group 1 - | - | - | No driving if arrhythmia caused / is likely to cause incapacity. Resume driving only if cause identified and arrhythmia controlled for at least 4 weeks. | No driving if arrhythmia caused / is likely to cause incapacity. Resume driving only if cause identified and arrhythmia controlled for at least 4 weeks. | No driving / minimal symptoms / no restrictions. | No / minimal symptoms – no restrictions. | No driving until symptoms controlled. | No / minimal symptoms – no restrictions. | Recurrent arrhythmias causing syncope / presyncope – no driving until definite treatment or according to pacemaker / ICD guidelines. |
| | Group 2 - | - | - | No driving if arrhythmia caused / is likely to cause incapacity. Resume driving only if cause identified and arrhythmia controlled for at least 4 weeks. | No driving if arrhythmia caused / is likely to cause incapacity. Resume driving only if cause identified and arrhythmia controlled for at least 4 weeks. | No driving until symptoms controlled. | No / minimal symptoms – no restrictions. | Recurrent arrhythmias causing syncope / presyncope – no driving until definite treatment or according to pacemaker / ICD guidelines. |
| Ablation | Group 1 - | - | - | Resume driving after 2 days. | After recovery from the procedure. | No driving for 2 days after discharge. | No driving for 2 days. | - |
| | Group 2 - | - | - | No driving for 1 week. | After recovery from the procedure. | No driving for 1 week after discharge. | No driving for 4 weeks. | - |
| Pacemaker | Group 1 - | - | - | Driving allowed after adequate function and wound healing (no time limit). No driving for 1 week. | Can drive anytime. | No driving for 1 week, and correct pacemaker function. | No driving for 2 weeks. | No driving for 1 week. |
| | Group 2 - | - | - | Driving allowed after adequate function and wound healing (at least 2 weeks). No driving for 6 weeks. | No driving for 1 week (4 weeks if dependant or history of syncope). | Can drive anytime (but no driving for 4 weeks if pacemaker dependant). | No driving for 1 month, and correct pacemaker function. | No driving for 4 weeks. |

Adapted from: Watanabe E et al.10; DVLA 201833; Task Force members 200934; Epstein et al. 199635; Epstein et al. 200736; ... 2006/126/EC39; The Expert Group on Driving and Cardiovascular Disease40; Lococo et al.42; Canadian Council of Motor.
### Syncope and Cardiac Arrhythmias

**Group 1**

- **Post-implant:**
  - No driving for 3 months.

- **ICD therapies:**
  - 1. Appropriate: No driving for 3 months;
  - 2. Inappropriate: No driving until measures are taken to prevent inappropriate therapies.

- **No driving for:**
  - 1. After implant – 6 months.
  - 2. Lead revision – 1 month.
  - 3. Box change – 1 week.
  - 4. Appropriate ATP or shock, associated with symptoms, but no incapacity – 6 months.
  - 5. Any therapy with incapacity (ATP/shock; appropriate/inappropriate) – 2 years, except:
    - a) Inappropriate shocks because of AF / programing issues – 1 month
    - b) Appropriate ATP/shocks for VT/VF but steps to control arrhythmia were taken (antiarrhythmics, ablation) and no recurrence – 6 months.

- **Group 2**

  **Permanent ban.**
  - May drive if risk of events is <1%/year.

---

### Table 2: Continued

| Cardiovascular condition | Driving licence group | Europe | US | Canada | Australia | Japan |
|--------------------------|-----------------------|--------|----|--------|-----------|-------|
| EHRA (professional guideline) | EC recommendations 2013 (proposal to update Directive 2006/126/EC) | UK | Germany | Guideline | Proposal to update legal document | Guideline | Legal document | Guideline | Legal document | Guideline | Legal document | Guideline | Legal document |
| EHRA (professional guideline) | EC recommendations 2013 (proposal to update Directive 2006/126/EC) | UK | Germany | Guideline | Proposal to update legal document | Guideline | Legal document | Guideline | Legal document | Guideline | Legal document | Guideline | Legal document |

---

**Recommendations of driving restrictions in patients at risk of syncope and cardiac arrhythmias associated with sudden incapacity, in different countries. The type of document (legal or guidelines only) is also displayed.**

Adapted from: Watanabe E et al.10; DVLA 201833; Task Force members 200934; Epstein et al. 199635; Epstein et al. 200736; ... 2006/126/EC39; The Expert Group on Driving and Cardiovascular Disease40; Lococo et al.42; Canadian Council of Motor Transport Administration43; Austroads44; Oginosawa et al.45; Sumiyoshi.46 AF = atrial fibrillation; ATP = antitachycardia pacing; EC = European Commission; EHRA = European Heart Rhythm Association; VT = ventricular tachycardia.
Fewer data are available regarding the risk of sudden incapacitation associated with inappropriate ICD shocks. Data from a study performed in Japan suggest that only 0.7% of patients who experience inappropriate ICD therapies also have syncope, e.g. because of fast AF resulting in syncpe but terminated by ICD shock, or VF induced by inappropriate ICD shock-on-T-wave as a result of T-wave oversensing. The calculated RH for inappropriate ICD therapies associated with syncpe was <0.0008% for both primary and secondary prevention ICD indications, leading the authors to conclude that inappropriate ICD shocks should not result in a driving ban.

Current data suggest that there is an increased risk of ICD shocks early after ICD implantation – for both primary and secondary prevention – and following appropriate or inappropriate ICD shocks, but the risk rapidly diminishes over the next 6 months. Thijssen et al. analysed data from 2,786 patients with primary and secondary prevention ICDs. Using the societal threshold for the RH of 0.005%, the 95% CI of the annual RH following ICD implantation was always below the threshold for both primary and secondary prevention, suggesting that no specific period of restriction after implantation is appropriate for private drivers. For commercial drivers, the RH was always above the threshold, supporting a permanent driving ban. However, newer data on contemporary ICD patient populations with modern ICD programing – and a more contemporary estimated risk of syncpe associated with ICD shocks of 14% – suggest that the RH falls below 0.005% only 1 month after appropriate shocks. Thijssen et al. also estimated the RH after inappropriate shocks, but they assumed that the risk of syncpe associated with ICD shocks is identical (31%) regardless of whether the shock was appropriate or not, which likely resulted in significantly underestimated RH (the 95% CI of the annual RH fell below 0.005% at 1 month and 3 months for appropriate and inappropriate shocks, respectively). As mentioned, newer data suggest that driving restrictions may not be necessary after inappropriate shock therapy.

It is important to realise though that there are several important limitations regarding the RH assessment in patients with ICDs. First, as discussed, the RH threshold of 0.005% has been historically accepted for Canadian populations based on Canadian road traffic accident data from more than 30 years ago. Second, the risk of SCD and ICD shocks has been largely based on populations from the 1990s and early 2000s but there has been an almost 70% reduction in mortality in patients with coronary artery disease and heart failure in the last 20 years and a 44% reduction in SCD rates between 1995 and 2014 in patients with heart failure and reduced ejection fraction. These dramatic changes were a result of more effective drug treatment, e.g. angiotensin converting enzyme inhibitors, early revascularisation in patients with acute coronary syndromes, implementation of cardiac resynchronisation therapy, and so on. Indeed, in non-ischaemic dilated cardiomyopathy, the Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH) failed to show a benefit of ICDs in reducing mortality, compared with the 11-year older Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). However, the overall absolute 5-year mortality rate in the DANISH was approximately 10% lower than in the SCD-HeFT. As such, the risk of sudden incapacity while driving in contemporary patients with ICD may well be lower than the historical data upon which the current recommendations and legislations are based would suggest.

Based on the summary above, we think that the current driving restrictions for patients with ICDs holding a group 1 driving licence are, in some cases, too restrictive. We propose that the following driving restrictions should suffice for these patients, if they drive in countries where the road safety statistics are similar to the countries mentioned in Table 2:

- after ICD implantation or box-change (both primary and secondary prevention) = 1 week;
- following appropriate ICD shock whether or not associated with incapacity = 1 month; and
- following inappropriate ICD shock whether or not associated with incapacity = no restriction if cause corrected.

### Legislation and Disclosure of Patient Information

#### Driving Regulations and Expert Consensus Documents

In many countries driving regulations have evolved over time as new data on clinical outcomes have become available. For example, in the UK, driving with an ICD was initially completely prohibited. By 1994 driving was allowed 2 years after ICD implant and by 2000 the regulations evolved to allow driving 1 month after a primary prevention ICD and 6 months after a secondary prevention ICD. Regulations are made to provide a balance between the privilege of driving and the potential to harm others from driving. It can be argued that, based on cultural and social mentality, national legislation will find different levels of equilibrium between these two opposing forces. In addition to national regulations, professional bodies have published guidance relating to particular areas of interest, such as licensing in ICD patients. The different national regulations and physician recommendations are summarised in Table 2. In some areas there is general consensus on no professional driving for patients with ICDs, in other areas there is more variation.

In the UK, driving regulations are governed by the Driver and Vehicle Licensing Agency for England, Wales and Scotland, and Driver and Vehicle Agency for Northern Ireland. In Germany, assessment of fitness to drive is governed by the German Federal Highway Research Institute.
presence of “serious arrhythmias” (a condition left undefined), while patients with cardiac pacemakers may drive if adequate follow up and checks are established.24 The presence of ICDs or ablation of cardiac arrhythmias is not found anywhere in the Directive, which was issued before these interventions were widely implemented in clinical practice. The latest amendment of this Directive (Directive 2006/126/EC, Annex III), which is still in force, made no changes to these definitions.29 This Directive has been widely incorporated into several legal frameworks and was legally binding in some European countries. Fortunately, the European Council has undertaken efforts to update the Directive 2006/126/EC Annex III with more extensive, up-to-date and specific recommendations for driving in patients with cardiovascular diseases.41 These changes have already been implemented in those EU member countries where the prior legislation was in effect until very recently, e.g. Romania.41

The legal framework of driving restrictions in the US is highly variable between states as there is no over-ruled federal law governing licensing decisions on medically at-risk drivers. For example, some states have a Medical Advisory Board (MAB) to guide decisions, while others do not. In addition, in some states medical professionals review cases, while in others administrative staff perform reviews. In some states, MABs employ medical professionals (e.g. Maine, North Carolina), while in others it is administrative staff who employ medical professionals (e.g. Texas, Wisconsin). Other states have no MAB, but again it is either medical professionals who perform reviews (e.g. Oregon), or administrative staff (e.g. Ohio, Washington).41

In Canada, the individual provinces and territories can legally develop their own policies but for consistency a central body – The Canadian Council of Motor Transport Administrators – has established a Driver Fitness Overview Group to advise on uniform medical standards. These standards are highly detailed and, unusually, allow for the possibility of commercial driving in recipients of a primary prevention ICD, in subgroups where the annual risk of incapacitation is below 1%.42

In Australia, Austroads and the National Transport Commission have issued guidelines on driving in patients with cardiovascular diseases.43 In Japan, regulations for drivers with cardiovascular diseases are governed by a Road Traffic Act issued by the Japanese National Police Agency.70,71,85

**Patient Confidentiality and Duty to Report Non-adherence**

In general, it is a physician’s responsibility to be familiar with the regulatory framework in the country where they practise. They are responsible for informing the patient what regulations apply and whether the patient should be notifying the driving authorities of their condition.

Adherence with physician recommendations regarding driving is low in patients with ICD, with approximately one-third of patients not adhering to these recommendations.25 Patients frequently perceive the driving restrictions as a loss of independence and change in self-image. Often patients resume driving because of a misunderstanding about their condition and the risks involved, or because they think it is their decision not others to make.41 Education about the rationale for driving restrictions is important for ICD patients.

In a situation where a physician becomes aware that a patient is not adhering to the local driving code, an ethical issue arises about what to do. In the US, the recommended ethical action for doctors who are involved in the care of patients with conditions that constitute a ban from driving is to disclose that information to the police, after informing the patient, even if the patient refuses to obey.48 The reasoning is that ethical responsibilities of beneficence (do good and avoid evil) and non-maleficence (do no harm) take precedence over the principle of confidentiality in this setting. In Canada, disclosure of patients’ information by physicians is mandatory in most states, but not in all (for example, reporting is discretionary in Alberta, Nova Scotia and Quebec).31 In the UK, doctors should inform patients about conditions and treatments that might affect their ability to drive and remind them of their duty to tell the appropriate agency.41 If a patient refuses or is found not to have told the appropriate agency, doctors should ask for a patient’s consent to disclose information to the authorities, unless the information “is required by law or if it is not safe, appropriate or practicable to do so”.46 In Germany, because of confidentiality law, the doctor should only inform the patient regarding the loss of fitness to drive; informing the authorities is not permitted.22 In Japan, the doctor should advise patients not to drive if they have had syncope or are at risk of syncope. Also, the doctor is recommended to advise about conditions or treatments that might affect the patient’s ability to drive to the National Public Safety Commission (Watanabe E, personal communication).

**Conclusion**

Driving regulations for patients at risk of syncope and cardiac arrhythmias associated with sudden incapacity attempt to balance the perceived RH against protection of individual freedom and the right to drive. There is significant national variation in regulation and the approach to its implementation.

Much of the scientific data that back up current recommendations are historical and may not accurately reflect changes in vehicles and the driving environment, along with possible changes in societal acceptance of risk. In future, for private drivers, a method to estimate the individual RH while driving – based on individual assessment of the time spent behind the wheel, age, driving profile, car safety, and so on – may prove useful. The development of new technologies such as driverless vehicles may have an impact on society’s willingness to accept excess risk as a result of medical conditions.

**Clinical Perspective**

- There is significant national variation in regulation of fitness to drive in patients at risk of sudden incapacitation, and the approach to its implementation.
- Much of the scientific data that back up current recommendations are historical and may not accurately reflect changes in vehicles and the driving environment, along with possible changes in societal acceptance of risk.
- In future, methods to estimate the individual risk of harm while driving may prove useful.
- The development of new technologies such as driverless vehicles may have an impact on society’s willingness to accept excess risk as a result of medical conditions.
Clinical Arrhythmias

1. Brignole M, Moia A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1863-948. https://doi.org/10.1093/eurheartj/ehy137; PMID: 29563264.

2. Bayés de Luna A, Cournel P, Ledger JF. Ambulatory sudden death: delineating the pathophysiology of focal arrhythmia on the basis of data from 157 cases. Am Heart J 1998;117: 151–9. https://doi.org/10.1016/S0002-8703(98)80160-4; PMID: 9595078.

3. Bureau of Transportation Statistics. Number of U.S. Aircraft, Vehicles, Vessels, and Other Conveyances. Available at: www.bts.gov/airline-vehicle-and-other-conveyances/table-3003013; accessed 29 November 2017.

4. Redfern D, Bayley D, Roman K. A social status report on road safety 2015. WHO. 2015. Available at: www.who.int/injury/prevention/road_safety_status/2015/en/ (accessed 29 November 2017).

5. Department for Transport. Reported road casualties Great Britain 2017. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/744078/infographic-2017-annual-report.pdf (accessed 12 April 2019).

6. Watanabe E, Halkic A, Watanabe S. Driving restrictions in patients with implantable cardioverter defibrillators and pacemakers. J Arrhythm 2017;33:394–601. https://doi.org/10.1111/joa.12597; PMID: 28702507.

7. Simpson C, Dorain R, Gupta A, et al. Assessment of the cardiac patient for fitness to drive: sub-group executive summary of the joint ESC/AHA/ASE consensus statement on the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. J Am Coll Cardiol 2016;67:2283–91. https://doi.org/10.1016/j.jacc.2016.06.059; PMID: 26961791.

8. GOV.UK. International comparisons of road accidents (RAS52). 2018. Available at: www.gov.uk/government/statistical-data-sets/ras52-international-comparisons#international-data-sets (accessed 12 April 2019).

9. Soteriades ES, Evans JC, Larson MG, et al. Incidence and outcomes of cardiac arrest among patients with implantable cardioverter defibrillators. JAMA Intern Med 2017;177:902–7. https://doi.org/10.1001/jamainternmed.2016.8617; PMID: 27580228.

10. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology/American Heart Association/American College of Cardiology. Eur Heart J 2015;36:2793–867. https://doi.org/10.1093/eurheartj/ehv311; PMID: 26292429.